Biotech startups in the Asia-Pacific region are pioneering the use of extracellular vesicles (EVs) for drug delivery, leveraging their low immunogenicity, natural tissue targeting, and ability to cross biological barriers. Companies such as South Korea’s Shiftbio utilize AI-driven design and manufacturing platforms to optimize natural nanoparticle candidates, including mesenchymal stem cell-derived EVs for cancer immunotherapy. These advances promise improved targeting and efficacy compared to synthetic vehicles, advancing the field of next-generation drug delivery systems.